Abstract | AIMS: METHODS: IVCP was given monthly at a dose of 500 mg/m2 for 6 months. At the end of 6 months, IVCP was discontinued in case there was no response. Otherwise, IVCP was continued for every 2 months. Oral prednisone was given concurrently at 60 mg/m2 daily for 6 weeks and then 40 mg/m2 on alternate days for 4 weeks. Prednisone was then tapered to 10 mg/m2 alternate days and continued during the therapy period. RESULTS: Only 1 of these patients achieved remission after IVCP while 4 patients showed no response to IVCP. 2 patients who did not achieve remission progressed to end-stage renal disease ( ESRD) and 2 others who had not been treated with cyclosporine before underwent cyclosporine therapy. None of our patients has suffered from adverse effects of IVCP. CONCLUSION: We found that IVCP had a limited beneficial effect in treatment of steroid-resistant FSGS and it may be suggested that IVCP can be tried to treat steroid-resistant patients, also for patients with primary steroid resistance and those who do not respond to other immunosuppressive therapies.
|
Authors | M Buyukcelik, N Cengiz, H Dursun, M Soran, A K Bayazit, A Noyan, A Anarat |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 65
Issue 1
Pg. 7-12
(Jan 2006)
ISSN: 0301-0430 [Print] Germany |
PMID | 16429836
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Cyclophosphamide
- Prednisone
- Methylprednisolone
|
Topics |
- Administration, Oral
- Adolescent
- Anti-Inflammatory Agents
(administration & dosage)
- Child
- Child, Preschool
- Cyclophosphamide
(administration & dosage)
- Female
- Glomerulosclerosis, Focal Segmental
(drug therapy)
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Infant
- Injections, Intravenous
- Male
- Methylprednisolone
(administration & dosage)
- Prednisone
(administration & dosage)
- Pulse Therapy, Drug
- Treatment Outcome
|